ExCeL London ããŒã«ã® 2 ã¡ãŒãã«é¢ããäœçœ®ã« 2 æã® AAIC ãã¹ã¿ãŒããããæ±ãèªç¥çç ç©¶ã¯é¡äŒŒ â ç°ãªãã³ããŒãã䌌ãåããåçã®å³å¯ããäžæ¹ã¯é²èЧæéãéããŠçºè¡šè
ãšé¢ããåå è
ã®å®å®ããéãŸãããããããäžæ¹ã¯ãã³ãŒããŒäŒæ©ãžåããéäžã§äžäººãã¡ãããšç®ãããã ãã ãäž¡è
ãåããã®ã¯ç§åŠã§ã¯ãªããèŠèŠãã¶ã€ã³ã ã
AAIC æ¡æãåãããã¹ãŠã®èè
ã¯ã3 æäžæ¬ã®æ¡æãã 6 é±ç®ã«åãå®è·µçãªåãã«çŽé¢ããïŒãã¹ã¿ãŒã«äœã èŒãããïŒæé²ãæ±ºå®æžã¿ïŒã§ã¯ãªããæ°åã®ç«¶åè
ãããããŒã«ã§æ³šç®ãç²åŸããããã«ã©ã æ§æããããæ¬ã¬ã€ãã§ã¯ã3 ç§ãã¹ããåäžã®ããŒããŒå³ã®ããã®èŠèŠéå±€ãæªã vs åã€ã® 5 äŸãå¡åºžãªå³ã 1 æé以å
ã«ã¢ããã°ã¬ãŒããã AI ã¯ãŒã¯ãããŒã解説ããŸãã
AAIC ãã¹ã¿ãŒæ¯èŒ â å·Šã¯éç¶ãšããããã¹ãéå€ã§ 8 æã®å°ããªè³ç»åãå³ã¯ã¯ãªãŒã³ãªããŒããŒå³ã¬ã€ã¢ãŠãã§åäžã®ã¢ããã€ãã«ã¹ã±ãŒããšæå°éã®ãµã€ãããŒïŒå³ã¯ SciFig ã§çæïŒ
éææ§ã«é¢ããæ³šèšïŒæ¬èšäºã®å³ã¯ SciFig AI ã§çæããããã®ã§ãããæªãäŸ vs åªããäŸãã®æ¯èŒã¯æè²ç®çã® AI ã¢ãã¯ã¢ããã§ãããå®éã®åè³ãã¹ã¿ãŒã§ã¯ãããŸãããåŒçšããå»åŠçèšè¿°ã¯ãã¹ãŠæ»èªæžã¿ã®æ
å ±æºã«ãªã³ã¯ããŠããŸãã
1. AAIC 2026 ã«ããããåã€ãã®å®çŸ©ïŒåºåå²åœãš ISTAART 衚地
AAIC ã«ããããåã€ãã«ã¯ç¹å®ã®å®çŸ©ããããŸããScientific Programme Committee ã¯æ¡ææé²ã 6 ã€ã®æ¡æçµè·¯ã«å²ãæ¯ããŸãïŒ
å
¬åŒã¬ã€ãã©ã€ã³ (Accessed 2026-05-22)ïŒïŒ
Podium Presentation ã
Featured Research Sessions ïŒFRSïŒã
Perspectives Sessions ã
Clinical Toolbox ã
Poster Presentation ïŒæå€§ã³ããŒãïŒããããŠå¥æ ã®
Beyond the Data ããžã¥ã¢ã«ã¢ãŒããã©ãã¯ããããã®äžã«
ISTAART Fellow Awards ïŒ
ISTAART ã¡ã³ããŒã·ãã (Accessed 2026-05-22)ïŒããããè¥æç ç©¶è
ããã³ãã¬ãŒããŒããã®æé«è©äŸ¡æé²ã衚地ããŸãã
ã€ãŸããåã€ããã¹ã¿ãŒãšã¯ïŒïŒaïŒããŒã«ãæ©ãåå è
ã®æ³šç®ãä¿ã¡ãïŒbïŒèª°ããç«ã¡æ¢ãŸããæ±ºãã 90 ç§ã®ãã£ãšèŠã«èããïŒcïŒ3 ã¡ãŒãã«ã®ã¢ãããŒãè·é¢å
ã§åäžã®æç¢ºãªç§åŠççºèŠãäŒãããã®ã§ããç§åŠã¯æ¡æåã« SPC ã«ãã£ãŠãã¢ã¬ãã¥ãŒãããŠããŸãïŒãã¹ã¿ãŒã®ä»äºã¯ããã®äºåæ€èšŒãããç§åŠãèªè
ã®ãšã³ã²ãŒãžã¡ã³ããš Fellow Award ã§ã®å¯èŠæ§ã«å€æããããšã§ãã
æ¬ã¬ã€ãã¯ãåã€ããçµéšçã«æ±ããŸã â åºåã«é¢ããããã©ã®èŠèŠçç¹æ§ããšã³ã²ãŒãžã¡ã³ããçãããåºåå¥ã® AAIC çµè·¯ãŠã©ãŒã¯ã¹ã«ãŒããã³ Beyond the Data æçš¿æéã«ã€ããŠã¯ã
AAIC 2026 ãã¹ã¿ãŒèŠå®ãš Beyond the Data ã¢ãŒããã©ã㯠ãåç
§ããŠãã ããã
2. èŠèŠé局㮠3 ç§ãã¹ãïŒæ»èªè
ãèªãããæ±ºããæ¹æ³
3 ç§ãã¹ãã¯ãããããåŠäŒãã¹ã¿ãŒã»ãã·ã§ã³ã®éçšäžã®å¶çŽã§ããåå è
ãããªãã®æ²ç€ºæ¿ã®åãéãéããçŽ 3 ç§ã¡ãããšèŠã â ã¿ã€ãã«ã1 æã®å€§ããªç»åããããã 1 ã€ã®å€ªåã®çµæãèŠããçšåºŠã®æé â ãããŠç«ã¡æ¢ãŸããæ©ãç¶ããããæ±ºããŸããä»ã®ãã¹ãŠã¯ã圌ãããã®ã²ãŒããééããå Žåã«ã®ã¿æå³ãæã¡ãŸãã
嫿ã¯ãèŠèŠéå±€ã æ®é
·ãªã»ã©æç€ºç ã«ããå¿
èŠãããããšã§ããã¿ã€ãã« â äžéšã3 ã¡ãŒãã«ããèªãã倧ãã â ã¯ç 究課é¡ãŸãã¯äž»èŠçºèŠãå¹³æãªèšèã§è¿°ã¹ãŸãã1 æã®ããŒããŒå³ïŒè³ã€ã©ã¹ããã¡ã«ããºã æš¡åŒå³ããŸãã¯ãã€ãªããŒã«ãŒããããïŒããã¹ã¿ãŒã®äžå€®ãæ¯é
ããäžç®ã§çè§£ã§ãã倧ããã§ãã1 ã€ã®å€ªåã®çºèŠå£°æãããŒããŒå³ã«é£æ¥ããŸããä»ã®ãã¹ãŠ â æ¹æ³ãè£å©å³ãåèæç® â ã¯ããå°ãããäºæ¬¡çãªäœçœ®ã«ãããŸãã
AAIC èªç¥çãã¹ã¿ãŒäžã®ã¢ã€ãã©ããã³ã°ããŒããããïŒã¿ã€ãã«ãšäž»èŠãªã¢ããã€ãçºèŠã®ããããŸãŒã³ãå¯ãªæ¹æ³ããã¹ãã®ã³ãŒã«ããŸãŒã³ã䌎ã F ãã¿ãŒã³èªã¿ïŒå³ã¯ SciFig ã§çæïŒ
åŠäŒãã¹ã¿ãŒã«é¢ããçŒçéåç ç©¶ã¯ãçµéšè±å¯ãªçºè¡šè
ãããŒã«ã§æ°ã¥ããŠããããšãè£ä»ããŸãïŒèªè
㯠F ãã¿ãŒã³ã§ã¹ãã£ã³ããã¿ã€ãã«ãšå·Šäž 4 åã® 1 ã匷ãåºèŠãããã®åŸå·Šç«¯ãéããŠããå³ãžã¹ã€ãŒãããŸãïŒ
Pernice et al. 2017 J Eye Mov Res (Accessed 2026-05-22) â 2026-05-22 ã¢ã¯ã»ã¹ïŒãå〠AAIC ãã¹ã¿ãŒã¯ãããå°éããŸã â ã¿ã€ãã«ãäžéšã«ãŸããããããŒããŒå³ãå·Šäžãäžå€®äžãåºå®ããäž»èŠçºèŠã F ãã¿ãŒã³ã®æåã®äžéãçå°ããå Žæã«åº§ããŸããErren ãš Bourne ã®å€å
žãTen simple rules for a good posterãïŒ
PLOS Comp Biol 2007 (Accessed 2026-05-22) â 2026-05-22 ã¢ã¯ã»ã¹ïŒã¯å¥ã®è§åºŠããåãç¹ãè¿°ã¹ãŠããŸãïŒãã¹ã¿ãŒã¯çºæ³¡ã³ã¢ã«è²Œãä»ããè«æã§ã¯ãªããèŠèŠçãªè°è«ã§ãã
3. æ
å ±å¯åºŠïŒå〠AAIC ãã¹ã¿ãŒã«ã¯ãå°ãªãããšãå€ãã
ãã¹ã¿ãŒã 3 ç§ãã¹ãã«å€±æããæãäžè¬çãªçç±ã¯æ
å ±å¯åºŠã§ãã10 ãã€ã³ããã©ã³ãã§ 800 èªã®æ¹æ³ããã¹ããèŒãããã¹ã¿ãŒã¯ã3 ã¡ãŒãã«ããèªããã90 ç§ã§åžåããã®ã¯äžå¯èœã§ãã200 èªãšåŒ·åãªèŠèŠã¹ããŒããåãããã¹ã¿ãŒã¯ãèªã¿ããã ã〠ãšã³ã²ãŒãžã¡ã³ããéã â æ»èªè
ã¯ãŸãã«ãã®ãã¬ãŒããªããè©äŸ¡ããŸãã
èŠåŸã¯ããã¹ãŠã®ããã¹ããããã¯ã«ãããã¯ã©ãã«ä»ãå³ã1 ã€ã®æããŸãã¯å®å
šãªåé€ã«çœ®ãæãããããïŒããšåãããšã§ããä¿®è«ã®ç« ã®ããã«èªããæ¹æ³ã»ã¯ã·ã§ã³ã¯ã氎平暡åŒå³ã«ãªãã¹ãã§ãïŒ5 ã¹ãããã5 ããã¯ã¹ã5 ç¢å°ãã°ã©ãã説æããçµææ®µèœã¯ãã°ã©ããš 1 ã€ã®è§£éæã«ãªãã¹ãã§ãã5 ã€ã®ç®æ¡æžãã®çµè«ã¯ã1 ã€ã®çºèŠå£°æã«ãªãã¹ãã§ãã
æ
å ±å¯åºŠã®æ¯èŒïŒå·Šã¯ã¢ããã€ãã«ã¹ã±ãŒããèšè¿°ãã 500 èªã®ããã¹ãã®å£ãå³ã¯åãå
容ã 1 ã€ã®ã¡ã«ããºã æš¡åŒå³ãš 3 ã€ã®ç®æ¡æžãã«ïŒå³ã¯ SciFig ã§çæïŒ
åç
§åºæºã¯ Mike Morrison ã® #betterposter ã ãŒãã¡ã³ãïŒ2019 幎ïŒã§ãåäžã®èŠåºãçºèŠããã¹ã¿ãŒäžå€®ã«çœ®ãããµããŒã詳现ãçããµã€ãããŒã«çœ®ãããšãææ¡ããŸãããçŽç²ãª betterposter ãã©ãŒãããã¯èªç¥çç ç©¶ã§ã¯ãŸã ãŸãã§ãããæ ¹åºã«ããååïŒ1 ã€ã®çºèŠãæ¯é
çããµããŒã詳现ãåŸå±çïŒãããããã¹ãŠã® Congress ã§åã€ãã¹ã¿ãŒãçããã®ã§ãã
4. åäžã®ããŒããŒå³ã®åïŒè³ãã¡ã«ããºã ããã€ãªããŒã«ãŒ
ãã¹ãŠã®å〠AAIC ãã¹ã¿ãŒã«ã¯ãä»ã®ãã¹ãŠãçµç¹åãã 1 ã€ã®ããŒããŒå³ããããŸããæå€§ã®èŠèŠèŠçŽ ã§ããã¹ã¿ãŒé¢ç©ã® 30ã50% ãå ããåå è
ãäœããèªãåã« 3 ã¡ãŒãã«ããèŠããã®ã§ããããŒããŒã®åšãã«ã¯ãããå°ããªãµããŒãããžã¥ã¢ã«ããã©ãã£ããåããŸãã
ããŒããŒå³ã¯ããªãã®ç§åŠçã¹ããŒãªãŒã 1 æã®ç»åã«å§çž®ãããå Žæã§ããããŸããæã¢ããã€ãæäœè©ŠéšãªãïŒäž»èŠãšã³ããã€ã³ãæ²ç·ãéãã詊éšã¹ããŒãããã©ã³ã¹ã¬ãŒã·ã§ãã«ã¡ã«ããºã ç ç©¶ãªãïŒä»å
¥ç¹ã匷調ããã¢ããã€ãã«ã¹ã±ãŒããŸãã¯ã¿ãŠäŒæå³ããªãã¯ã¹ãªãïŒçºèŠãã©ãã«ä»ããã UMAP ãããŒãããããTREM2 / ãã¯ãã°ãªã¢ç ç©¶ãªãïŒç¹å®ã®ããŒã«ãŒã瀺ããçŸæ£é¢é£ãã¯ãã°ãªã¢ã·ã°ããã£ãŒããã€ãªããŒã«ãŒç ç©¶ãªãïŒææ¡ããã«ãããªãã瀺ãã CSF p-tau ãŸãã¯ã¢ããã€ã PET å¯èŠåã
AAIC ãã¹ã¿ãŒã¬ã€ã¢ãŠãïŒ60% ã®é¢ç©ãå ãã倧ããªäžå€®ã®ã¢ããã€ã-ã¿ãŠããŒããŒå³ããããå°ããªã€ã³ãããæ¹æ³ãçµæãçµè«ã¢ãžã¥ãŒã«ãéåçãããŒã§å²ãïŒå³ã¯ SciFig ã§çæïŒ
æ£ããããŒããŒãéžã¶ããšã¯ãããªããäžãäžã§æãçµæçãªãã¶ã€ã³æ±ºå®ã§ããäžæã«éžã°ããããŒããŒã¯ãæ®ãã®ãã¹ã¿ãŒãããäžçæžåœåãããŠè£ãããŸãïŒããŸãéžã°ããããŒããŒã¯ãæ®ããã»ãŒèªæã«ããŸããAAIC ç¹åã®ããŒããŒã¿ã€ãã«ã€ããŠã¯ã
AAIC 2026 åãã¢ããã€ãã»ã¿ãŠã¡ã«ããºã å³è§£ ãåºçå質ã®ã«ã¹ã±ãŒãããã³ã¿ãŠäŒæããŒããŒãæ±ãã
AAIC 2026 åã TREM2 ãã¯ãã°ãªã¢ã»ç¥çµççå³ ãå
ç«çŠç¹æçš¿ã®ããã®ãã¯ãã°ãªã¢ã·ã°ããªã³ã°ããŒããŒãæ±ããŸãã
5. æªã vs åã€ïŒèªç¥çãã¹ã¿ãŒãã¿ãŒã³ãã 5 ã€ã®äžŠåäŸ
5 ã€ã®ãã¶ã€ã³å€±æã«ããŽãªãŒããã¹ãŠã® AAIC ãã¹ã¿ãŒã»ãã·ã§ã³ã§ç¹°ãè¿ãçŸããããããã«æ¢ç¥ã®ä¿®æ£æ³ããããŸãã以äžã®åãã¢ã¯æªãããŒãžã§ã³ïŒåè€åã®å·ŠïŒãšåã€ããŒãžã§ã³ïŒå³ïŒã瀺ããŸãããã¹ãŠæè²çš AI ã¢ãã¯ã¢ããã§ãã â å®éã«æçš¿ããããã¹ã¿ãŒããæœåºããããã®ã§ã¯ãªããç¹å®ã®ç ç©¶ãžã®æ¹å€ãšããŠèªãŸããã¹ãã§ã¯ãããŸããã
ã㢠1 â IHC åçã®éå° vs åäžã®ä»£è¡šããã«
IHC ã¬ã€ã¢ãŠã â å·Šã¯æ··æ²ãšããã°ãªããã«éå°ããªãã³ã°ããã 12 æã®ã¢ããã€ããã©ãŒã¯ IHC åçãå³ã¯ 1 æã®å€§ããªä»£è¡šãã©ãŒã¯ç»åãš 1 æã®ã©ãã«ä»ãæš¡åŒå³ïŒå³ã¯ SciFig ã§çæïŒ
æªã ïŒãå
šéšè£éºã«èŒã£ãŠããããšããçç±ã§ 4Ã3 ã°ãªããã«è©°ã蟌ãŸããã¢ããã€ããã©ãŒã¯ã® 12 æã®å°ã㪠IHC åçããµã ãã€ã«ãµã€ãºã§ã¯ãã¹ãŠã®ãã©ãŒã¯ãåãã«èŠããïŒèª°ãããããæ¯èŒããŸãããå〠ïŒã¹ã±ãŒã«ããŒä»ãã® 1 æã®å€§ããé©åã«ããªãã³ã°ããã代衚 IHC åçãšã匷調ããããã©ãŒã¯åœ¢æ
ã®ã©ãã«ä»ãæš¡åŒå³ 1 æãä»ã® 10 æã®åçã¯è£éºãŸãã¯ããŒã¯ã«å±ããŸãã
ã㢠2 â éç¶ãšããã¡ã«ããºã å³ vs ç°¡ç¥åãããããŒããŒç
ã¡ã«ããºã ã¬ã€ã¢ãŠã â 巊㯠40 ååãšéãªãç¢å°ãæã€å¯ãªã¢ããã€ã-ã¿ãŠã«ã¹ã±ãŒããå³ã¯ä»å
¥ç¹ã匷調ããã 6 ããŒãã®ã¯ãªãŒã³ãªã«ã¹ã±ãŒãïŒå³ã¯ SciFig ã§çæïŒ
æªãããŒãžã§ã³ã¯ãAPP ãã Aβ ãªãªãŽããŒãã¿ãŠé«ãªã³é
žåãç¥çµççãŸã§ã®ãã¹ãŠã®ååã 1 æã®å³ã«è©°ã蟌ã¿ãã©ã®åå è
ã 3 ç§ã§åžåã§ããŸãããåã€ããŒãžã§ã³ã¯ããã SciFig ã§ã¬ã³ããªã³ã°ãããã«ã¹ã±ãŒãã«èžçãã6 ã€ã®ã¢ã³ã«ãŒããŒããã©ãã«ä»ããããç¹å®ã®ä»å
¥ç¹ã匷調ãããŸã â å§åŠ¹ç·š
ã¢ããã€ãã»ã¿ãŠã¡ã«ããºã ã¬ã€ã ã§äœ¿ãããã®ãšåãæ§æçã¢ãããŒãã§ããåºçå質㧠3 ã¡ãŒãã«ããèªããŸãã
å³è¡šãšã³ãã³ã¹ãå®è·µã§èŠã
æ¢åã®ç§åŠå³è¡šã8Kãžã£ãŒãã«å質ã«ã¢ããã¹ã±ãŒã«ãã€ã³ãã€ã³ãããªã«ã©ãŒãã©ãã«å€æŽã
ããŒã«ãæ¢çŽ¢
ã㢠3 â æ¹æ³ããã¹ãã®å£ vs ã¹ããŒã眮ãæã
æ¹æ³ã»ã¯ã·ã§ã³ â 巊㯠CSF ãã€ãªããŒã«ãŒã¯ãŒã¯ãããŒãèšè¿°ãã 10pt ããã¹ãã® 500 èªã®å£ãå³ã¯ 5 ããã¯ã¹ãšæ£è
æ°ãåããæ°Žå¹³ CONSORT 圢åŒã¹ããŒãïŒå³ã¯ SciFig ã§çæïŒ
æªã ïŒCSF Aβ42 / p-tau ã¢ãã»ã€ãã¹ã¯ãªãŒãã³ã°ããšã³ããŒã«ã¡ã³ããèšè¿°ãã 10 ãã€ã³ã Calibri ã§ 500 èªã®æ¹æ³ â 3 ã¡ãŒãã«ããèªããããã¹ãŠã®åå è
ã«ã¹ããããããŸããå〠ïŒ5 ãã§ãŒãºïŒã¹ã¯ãªãŒãã³ã° â ãšã³ããŒã«ã¡ã³ã â ãã€ãªããŒã«ãŒã¢ãã»ã€ â 远跡 â è§£æïŒãšåç¢å°ã«åå è
æ°ãåããæ°Žå¹³ CONSORT 圢åŒã¹ããŒãã8 åã§ã¯ãªã 8 ç§ã§æ¹æ³ãææ¡ã§ããŸãã
ã㢠4 â æ··æ²ãšããã«ã©ãŒãã¬ãã vs èŠåŸããèªç¥çç ç©¶ãã¬ãã
ã«ã©ãŒãã¬ãã â å·Šã¯è³ããã«éã§äžè²«æ§ãªã䜿ãããæ··æ²ãšãã 8 è²ã¬ã€ã³ããŒãå³ã¯æå³ã®äžè²«æ§ãä¿ã€èŠåŸãã玫-ãã£ãŒã«-çœãã¬ããïŒå³ã¯ SciFig ã§çæïŒ
æªã ïŒè³ããã«éã§äžè²«æ§ãªã䜿ããã 8 ã€ã®åœ©åºŠã®é«ãã¬ã€ã³ããŒè² â èµ€ãããå Žæã§ã¯ãã¢ããã€ãè² è·ããå¥ã®å Žæã§ã¯ãæ²»ç矀ããæå³ãããçŒç²Ÿç²åŽã 5 ç§ä»¥å
ã«å§ãŸããŸããåã€ ïŒæå¶ããã 3 è²ãã¬ããïŒAlzheimer's Association ã®çŽ«ãæ§ãããªãã£ãŒã«ã¢ã¯ã»ã³ããçœèæ¯ïŒã§ãã¹ã¿ãŒå
šäœã«äžè²«ããæå³ â 玫ã¯ã¢ããã€ãããã£ãŒã«ã¯ã¿ãŠãç°è²ã¯å¯Ÿç
§ãèµ€ã¯èŠåãŸãã¯ææã«äžæãããªã¹ã¯ã®ããã«äºçŽããŸãã
ã㢠5 â ææ§ãªèšè¿°çã¿ã€ãã« vs äž»èŠçºèŠã瀺ãèŠåºãã¿ã€ãã«
ãã¹ã¿ãŒã¿ã€ãã«ã®æ¯èŒ â å·Šã¯ææ§ãªèšè¿°çãªè€æ°è¡ã¿ã€ãã«ãå³ã¯å®£èšçèŠåºããLecanemab ã PET ã§ Aβ è² è·ã 60% æžå°ãïŒå³ã¯ SciFig ã§çæïŒ
æªã ïŒãæã¢ããã€ãã¢ãã¯ããŒãã«æäœçæ³ã§æ²»çãããæ©æã¢ã«ããã€ããŒç
æ£è
318 äŸã«ããããã€ãªããŒã«ãŒå€åã®ãã«ãã»ã³ã¿ãŒã¬ããã¹ãã¯ãã£ãè§£æããå〠ïŒãLecanemab ãæ©æã¢ã«ããã€ããŒç
ã§ã¢ããã€ã PET è² è·ã 60% æžå°ïŒ318 äŸã®ãªã¢ã«ã¯ãŒã«ãããŒã¿ããèŠåºãããŒãžã§ã³ã¯ãåå è
ãç«ã¡æ¢ãŸã決å®ãããåã«çºèŠãäŒããŸãã
ãã¿ãŒã³ïŒåã€ããŒãžã§ã³ã¯äœãæãéèŠããæ±ºå®ããä»ã®ãã¹ãŠãäºã®æ¬¡ã«èœãšããŸããæªãããŒãžã§ã³ã¯ãã®æ±ºå®ãæã¿ããã¹ãŠãå«ããããšããŸãã
# 倱æãã¿ãŒã³ æªãããŒãžã§ã³ åã€ããŒãžã§ã³ æ©èœããçç± 1 IHC åçã®éå° 4Ã3 ã°ãªããã« 12 æã®å°ããªãã©ãŒã¯ IHC 代衚 IHC 1 æ + ã©ãã«ä»ãæš¡åŒå³ 1 æ æ»èªè
ã¯ãã©ãŒã¯åœ¢æ
ã 30 ç§ã§ã¯ãªã 3 ç§ã§èŠã 2 ã¡ã«ããºã ã®è€éã éãªãç¢å°ãæã€ 40 åå ã¯ãªãŒã³ãªã«ã¹ã±ãŒãã6 ã¢ã³ã«ãŒããŒããä»å
¥ã匷調 åäžã®çŠç¹ â 3 ã¡ãŒãã«ã§èªãã 3 æ¹æ³ããã¹ãã®å£ 10pt Calibri ã§ 500 èª åå è
æ°ãåããæ°Žå¹³ 5 ãã§ãŒãºã¹ããŒã 8 ç§ã§æ¹æ³ãææ¡ 4 ã«ã©ãŒãã¬ããã®æ··æ² äžè²«æ§ãªã䜿ããã 8 è²ã®åœ©åºŠã¬ã€ã³ã㌠æå³ãæã€ 3 è²ãã¬ããïŒçŽ« / ãã£ãŒã« / çœïŒ ããã«éã§äžè²«ããã¢ã³ã«ãŒãç®ãèŠã€ãã 5 ææ§ãªèšè¿°ã¿ã€ãã« ããã€ãªããŒã«ãŒå€åã®ã¬ããã¹ãã¯ãã£ãè§£æâŠã ãLecanemab ãã¢ããã€ã PET è² è·ã 60% æžå°âŠã åå è
ãç«ã¡æ¢ãŸã決å®ãããåã«èŠåºãã®çµæãææ
Tip
åºåãåã¡åãããã« 5 ã€ã®å€±æãã¿ãŒã³ãã¹ãŠãä¿®æ£ããå¿
èŠã¯ãããŸãããçŸåšã®ãã©ããã§ æãæ·±å»ãª 1ã2 ã€ã®å€±æãéžã³ ãããã« AI æ¯æŽã®æ¹åãéäžããŸãããã1 ã€ã®ãã¿ãŒã³ã 80%ãä»ã 60% æ£ããä»äžãããã¹ã¿ãŒã¯ã5 ã€ãã¹ãŠã 50% ã«ãããã¹ã¿ãŒãäžåããŸã â 3 ç§ãã¹ãã¯æšªäžŠã³ã®éšåæ¹åã§ã¯ãªããçŠç¹ãçµã£ã決å®ãè©äŸ¡ããŸãã
6. ãããã AAIC ãã¹ã¿ãŒå€±æ Œäºç±ïŒåååããã©ã€ãã·ãŒããšã³ããŒãŽ
ãã¶ã€ã³å質ãè¶
ããŠãAAIC ãš Alzheimer's Association ã¯ãèŠèŠçã«ç£šãããŠãããã«é¢ããããã¹ã¿ãŒãå€±æ Œããããå§å¡äŒæªçœ®ãåŒãèµ·ããããããç¹å®ã®æçš¿èŠåãå·è¡ããŸãã
åååãšåæ¥ããŽã¯æšå¥šãããªããçŠæ¢ãããŠããŸãã å
šäœã§äžè¬åïŒåœéäžè¬åãINNïŒã䜿çšããŠãã ãã â lecanemab ã§ãLeqembiãã§ã¯ãªããdonanemab ã§ãKisunlaãã§ã¯ãªããaducanumab ã§ãAduhelmãã§ã¯ãªããèŽè¡ã INN ãèªèããªãå Žåãæåã®äœ¿çšæã«æ¬åŒ§æžãã§ 1 åãã©ã³ãåã«èšåããããšã¯èš±å®¹ãããŸããããã¹ã¿ãŒæ¬äœããã¹ãŠã®å³ã©ãã«ãçµè«ã¯ INN ã䜿çšãã¹ãã§ãã補è¬äŒç€ŸããŽã¯ãã¹ã¿ãŒæ¬äœã«å±ããŸãã â ã¹ãã³ãµãŒè¬èŸã¯å°ããªé瀺ããã¿ãŒã«å
¥ããŸãã
æ£è
ç¹å®æ
å ±ã¯è¶ããŠã¯ãªããªãäžç·ã§ãã åå è
ã®é¡ãåããåçãèå¥å¯èœãªé è骚ãé¡é¢åæ§æã䌎ã MRI ããŒã¿ã»ããããŸãã¯ååãç
é¢ ID ãå«ãã¹ãã£ã³ã©ãã«ã¯ãHIPAA ãã©ã€ãã·ãŒã«ãŒã«ïŒ
HHS HIPAA ãã©ã€ãã·ãŒã«ãŒã« â 2026-05-22 ã¢ã¯ã»ã¹ïŒããã³ãšãŒãããã®é¡äŒŒ GDPR èŠä»¶ã«éåããŸããæ§é MRI ã®é¡é¢é€å»ïŒdefacingïŒãšããã¹ã¿ãŒäžã®ãã¹ãŠã®ç»åããã®ã¢ã¯ã»ãã·ã§ã³çªå·ããã³ DOB ã®åé€ã¯é亀æžã§ããæã¢ããã€ã詊éšããã® ARIA ã€ã¡ãŒãžã³ã°ã¯ãå
ã® DICOM ããããŒã«èå¥åãæ®ãããšãå€ããããç¹ã«æŒæŽ©ãªã¹ã¯ããããŸã â æ£è
ã¬ãã«ã®ç»åãåçŸããåã« IRB ã«ç¢ºèªããŠãã ããã
Encore ãšãµã©ãã¹ã©ã€ã¹èŠåãé©çšãããŸãã AAIC ã¯æçš¿æã«æ£ãããã©ã°ãç«ãŠãããå Žåã«çã® encore ãåãå
¥ããŸããããã©ã°ãªãã§ã®å
¬éæžã¿ããŒã¿ã®åæç€ºãã1 ã€ã®ã³ããŒããè€æ°ã®èãæé²ã«åå²ããããšã¯ããã¹ã¿ãŒãåŒãäžããããèªèãããçç±ã§ãã
æåŸã®å€±æ Œäºç± â
å®éšçãšããã³ã¹ãšããŠæç€ºããã AI çæã³ã³ãã³ã ãSciFig ããã³é¡äŒŒããŒã«ã¯ãã¡ã«ããºã å³ãè§£ååŠçæš¡åŒå³ãæŠå¿µå³ã«é©åã§ããå®éã®çµç¹åŠãIHCãMRIãPET ããŒã¿ã®ä»£ããã« AI åºåã§ä»£æ¿ããã®ã¯é©åã§ã¯ãããŸãã â ããã¯ç§åŠçäžæ£è¡çºã«ãªããŸããåãå
¥ãããã AI å³äœ¿çšã®å®å
šãªãã¬ãŒã ã¯ãŒã¯ã«ã€ããŠã¯ã
AI çæå³ã¯ãžã£ãŒãã«ã§èš±å¯ãããŠãããïŒ ãåç
§ããŠãã ããã
7. å〠AAIC 2026 ãã¹ã¿ãŒã®ããã®ãã¶ã€ã³ã·ã¹ãã ïŒè²ãã¿ã€ãã°ã©ãã£ãã¹ããŒã¹
åã€ãã¹ã¿ãŒã¯ã¿ã€ããªãã¶ã€ã³ã·ã¹ãã ã«åŸããŸãã3 ã€ã®ã«ãŒã«ãèªç¥çç ç©¶ã®æèã§éèŠãªå€§éšåãã«ããŒããŸãã
è² ïŒ3 è²ãéžã³ãããã«åºå·ããŸããããå
žåç㪠AAIC ãã¬ã³ããªãŒãªãã¬ãã㯠1 ã€ã®æ¿ããã©ã€ããªãŒïŒAlzheimer's Association ã®çŽ«ããŸãã¯æ·±ããã€ããŒïŒã1 ã€ã®ã¯ãŒã«ã¢ã¯ã»ã³ãïŒæ§ãããªãã£ãŒã«ãŸãã¯ã»ãŒãžïŒãçœã§ãããã©ã€ããªãŒãããããŒãšäž»èŠã©ãã«ã«ãã¢ã¯ã»ã³ãããã€ã©ã€ãã«ãçœãèæ¯ã«äœ¿çšããŸããã¬ã€ã³ããŒãã¬ãããèµ€ã®éå°äœ¿çšïŒäŒçµ±çã«èŠåã瀺ããéå°äœ¿çšã§æåºŠãäžããïŒãè²èŠããªã¢ããªãŒãã§ãã¯ã«å€±æããè²çµã¿åãããé¿ããŠãã ãããIHC ãš PET ãªãŒããŒã¬ã€ã«ã¯ãåéæšæºã®ã«ã©ãŒãããïŒäŸãã° SUVR ã¹ã±ãŒã«çšã®éããèµ€ãžã®çºæ£ïŒã«çãŸããŸãããã
ã¿ã€ãã°ã©ã㣠ïŒ2 ã€ã®æžäœïŒ1 ã€ã»ãªãã1 ã€ãµã³ã»ãªãïŒãéžã³ãŸããéå±€ã¯ãµã€ãºã§ç¢ºç«ããæ°ãããã©ã³ããå°å
¥ããããšã§ã¯ãããŸãããã¿ã€ãã«ã¯ 80ã100ptãã»ã¯ã·ã§ã³ããããŒã¯ 36ã44ptãæ¬æããã¹ãã¯æäœ 24ã28ptïŒ10ã12pt 㯠3 ã¡ãŒãã«ããèŠããŸããïŒããµã³ã»ãªãïŒHelveticaãLatoãOpen SansãInterïŒã¯é è·é¢ããã»ãªãããèªã¿ãããã§ããã€ã¿ãªãã¯ã¯åŒ·èª¿ãŸãã¯çš®åã®ã¿ã«äœ¿ããŸãã
ã¹ããŒã¹ ïŒå¯å€§ãªç©ºçœããããã§ãã·ã§ãã«ãªãã¹ã¿ãŒãšã¢ããã¥ã¢ã®ãã¹ã¿ãŒãåããŸããããŒãžã³ 5ã7 cmãããã«éé â¥3 cmãããã¹ããå¢çã«è§Šããªãå
éšããã£ã³ã°ãã¹ããŒã¹ãåããããšããæ¬èœã«æµæããŠãã ãã â ãããããã¹ãã®å£ãçããã®ã§ãã
ãšã³ã¿ãŒãã©ã€ãºãã¶ã€ã³ãœãããŠã§ã¢ãªãã§åºçå質ã®ãã¹ã¿ãŒå³ãæ§ç¯ããäºç®éèŠããŒãžã§ã³ã«ã€ããŠã¯ã
äºç®å
ã§ Nature æ°Žæºã®å³ãäœæããæ¹æ³ ãåç
§ããŠãã ããã
8. AI ã§å¡åºžããåã€ãã¹ã¿ãŒãžïŒ1 æéã§
ãã©ãããã¹ã¿ãŒå³ããããã¯çŽãã¹ãããããããã¯åã€ããžã1 æé以å
ã§å€ããå®è·µçãªã¯ãŒã¯ãããŒã§ããåã¹ããã㯠5ã20 åããããå
šã·ãŒã±ã³ã¹ã¯çŠç¹ãçµã£ã 1 ã€ã®äœæ¥ãããã¯ã«åãŸããŸãã
ã¹ããã 1ïŒ3 ç§ãã¹ãã«å€±æãã 1 ã€ã®å³ãç¹å®ãã
ïŒ5 åïŒ3 ç§ãã¹ãåºæºã§ æã匱ãåäžã®å³ ãéžã³ãŸã â éåžžã¯ã¢ããã€ã-ã¿ãŠã«ã¹ã±ãŒãã詊éšã¹ããŒããIHC ããã«ããŸãã¯çŽ æ©ãäŒéããã«æãé¢ç©ãæ¶è²»ããè³ã¢ãã©ã¹å³ã§ãããã¹ãŠãã¢ããã°ã¬ãŒããããè¡åã«æµæããŸãããïŒ1 ã€ã®ããŒããŒãžã®éäžçãªçœ®ãæãã¯ãå€ãã«ãããæ¡æ£çãªç£šããäžåããŸãã
ã¹ããã 2ïŒå³ã 1 æã§è¡šçŸãã
ïŒ5 åïŒå³ãäœãäŒããã¹ãããè¿°ã¹ã 1 æãæžããŸã â äŸïŒãAPP åæãã Aβ ãªãªãŽããŒåéãã·ããã¹åªå€±ãŸã§ã®ã¢ããã€ãã«ã¹ã±ãŒãã§ãæ Aβ æäœã®ä»å
¥ç¹ããªãªãŽããŒæ®µéã«ç€ºããããã®æãããªãã® SciFig ããã³ããã®è骚ã«ãªããŸãã
ã¹ããã 3ïŒSciFig ã§åçš¿ãçæãã
ïŒ15 åïŒ
SciFig ã®å³ãšã³ãã³ãµãŒ ãéããŠçŸåšã®åŒ±ãå³ãã¢ããããŒããããã
Text-to-Figure ãéããŠæ§é åããã³ããã貌ãä»ããŸãã
ã¢ããã€ã-ã¿ãŠã¡ã«ããºã ã¬ã€ã ãš
TREM2 ãã¯ãã°ãªã¢ã¬ã€ã ã«ã¯äž¡ãããã¯ã«äœ¿ããããã³ãããæã£ãŠããŸããåååºåã¯å
žåçã«ã¯ 70%-æ£ç¢ºãªåºçºç¹ã§ãã
ã¹ããã 4ïŒSciFig ãã¯ã¿ãŒãã£ã³ãã¹ã§èª¿æŽãã
ïŒ20 åïŒSciFig ã®ãã¯ã¿ãŒãã£ã³ãã¹ã§çµæãéããŸããç¹å®ã®ã³ã³ã¹ãã©ã¯ããã³ããŒãããŸãã¯ãã€ãªããŒã«ãŒã«åãããŠã©ãã«åã倿ŽããŸãããã¹ã¿ãŒã® 3 è²ã·ã¹ãã ã«åãããŠãã¬ããã調æŽããŸããããã«ã¹ããŒã¹ã«åãããŠãªãµã€ãºããŸããã¬ã€ã€ãŒå SVG ãŸã㯠8K PNG ã«æžãåºããŸããIllustrator ãžã®åŸåŸ©ã¯äžèŠ ã
ã¹ããã 5ïŒãã¹ã¿ãŒã¬ã€ã¢ãŠãã«é
眮ãã
ïŒ15 åïŒæ°ããå³ãã¬ã€ã¢ãŠãã«é
眮ããããŒããŒã« 30ã50% ã®é¢ç©ãäžãããã飿¥ããã«ããªãµã€ãºããæ°ããããŒããŒã貌ãä»ããããã«èŠããã®ã§ã¯ãªãã¢ã³ã«ãŒãšãªããã空çœãå調æŽããŸãã
åèšïŒçŽ 1 æéãçµæã¯ãåã€åè£ãšããŠããªãã®ãã¹ã¿ãŒãåºå®ãã 1 ã€ã®å³ã§ããæ°èŠ SciFig ã¢ã«ãŠã³ãã¯
150 ã¹ã¿ãŒã¿ãŒã¯ã¬ãžãã ã«å ã
æ¯æ¥ 50 ãªãã£ã«ã¯ã¬ãžãã ã§å§ãŸããŸã â åäžã®ããŒããŒå³ã¢ããã°ã¬ãŒãã¯å埩å«ããŠéåžž 30ã50 ã¯ã¬ãžãããæ¶è²»ããŸãããã倧éã®ããŒãºã«ã€ããŠã¯
æéããŒãž ã確èªããŠãã ããã
ä»ããç§åŠå³è¡šãäœæ
èªç¶èšèªã§ç§åŠå³è¡šã説æ â æ°åã§åºçå¯èœãªã€ã©ã¹ããååŸã
ç¡æã§è©Šã
9. Beyond the DataïŒAAIC ã®ã¢ãŒããã©ãã¯ãžã®è¶å¢
åã€ãã¹ã¿ãŒãã¶ã€ã³ãš Beyond the Data ããžã¥ã¢ã«ã¢ãŒãã³ã³ãã¯ãã»ãšãã©ã®èè
ãæ°ã¥ããããå€ãã®åºç€ååãå
±æããŠããŸããBeyond the Data ã¯ãèªç¥çç ç©¶ã®èžè¡çè§£éã®ããã® Alzheimer's Association ã®äžŠè¡æ¡æçµè·¯ã§ãïŒ
å
¬åŒè©³çް (Accessed 2026-05-22) â 2026-05-22 ã¢ã¯ã»ã¹ïŒâ çããŒã¿ãæç€ºããã®ã§ã¯ãªãç§åŠçæŠå¿µãå¯èŠåããçµµç»ãã€ã©ã¹ãã圫å»ãåçãããžã¿ã«ã¢ãŒãã審æ»å¡ã¯ 3 ã€ãè©äŸ¡ããŸãïŒç§åŠçæ£ç¢ºããèžè¡ç䟡å€ããããŠåäžæŠå¿µãäŒéãããæçãã
ãã® 3 ã€ç®ã®åºæº â åäžæŠå¿µã®æçã â ã¯ãå〠Poster Presentation ãçããã®ãšåäžã§ããã¢ããã€ãã«ã¹ã±ãŒãå
šäœãTREM2 ã·ã°ããªã³ã°ãããã¯ãŒã¯å
šäœããã¹ãŠã®è©Šéšãšã³ããã€ã³ããäžåºŠã«æãããšãã Beyond the Data äœåã¯è² ããŸããåãããšã詊ã¿ã Poster Presentation ãè² ããŸããèŠèŠéå±€ãèŠåŸãããã¬ãããèŠåºããã¬ãŒãã³ã°ããäžã€ã®ããŒããŒã¢ã€ãã¢ãã«ãŒã«ã¯ãã¹ãŠå¢çãè¶ããŠè»¢çšã§ããŸãã
éãã¯ã2 ã€ã®ãã©ãŒãããã蚱容ãããã®ã§ããéåžžã® Poster Presentation ã¯ãèªèå¯èœãªç§åŠçæ§é ã§å®éšçãšããã³ã¹ãæ¹æ³ãçµæãå«ããå¿
èŠããããŸããBeyond the Data ã¯ã¹ã¿ã€ã«åãã¡ã¿ãã¡ãŒãææ
çå
±é³Žã蚱容ããŸã â ææãã®ãã¥ãŒãã³ãã¹ãã³ãã°ã©ã¹ã®ã³ãã¯ããŒã ãèšæ¶åªå€±ã®æœè±¡çã¬ã³ããªã³ã°ã匷ã Poster Presentation ããŒããŒå³ãæã€èè
ã¯ããã°ãã°ãã®åãæŠå¿µç»åãæ¬¡ã® Congress ã® Beyond the Data æçš¿ãžãšè²ãŠãŸããBeyond the Data ã®å®å
šãªèŠåã蚱容ã¡ãã£ã¢ãæçš¿æéãè©äŸ¡åºæºã«ã€ããŠã¯ã
AAIC 2026 ãã¹ã¿ãŒèŠå®ãš Beyond the Data ã¢ãŒããã©ã㯠ãåç
§ããŠãã ããã
10. ç¡æè©Šçš CTA ãš Congress åãã¹ã¿ãŒãã§ãã¯ãªã¹ã
å°å·ãããã¹ã¿ãŒã AAIC 2026ïŒ7 æ 12ã15 æ¥ïŒã®ããã« ExCeL London ã«çºéããåã«ç¢ºèªãã¹ã 12 é
ç®ãããã¯
AAIC 2026 ãã¹ã¿ãŒèŠå®ãš Beyond the Data ã¢ãŒããã©ã㯠æŠèгã«ç»å Žããã®ãšåããã§ãã¯ãªã¹ãã§ã â æçµèª¿æŽäžã¯ãããéããŠãããŸãããã
â æ¡æçµè·¯ç¢ºå®ïŒPodium / FRS / Perspectives / Clinical Toolbox / Poster / Beyond the DataïŒ
â ã¿ã€ãã«ã 3 ç§ãã¹ããééïŒ3 ã¡ãŒãã«ããèŠèªã宣èšçãäž»èŠçºèŠãå¹³æãªèšèã§ïŒ
â 1 ã€ã®ããŒããŒå³ãã¬ã€ã¢ãŠããåºå®ïŒãã¹ã¿ãŒé¢ç©ã® 30ã50%ãåºçæ°ŽæºïŒ
â 3 è²ãã¬ããããã¹ãŠã®ããã«ã§äžè²«é©çšïŒçŽ« / ãã£ãŒã« / çœãŸãã¯åçïŒ
â æå€§ 2 æžäœãæ¬æããã¹ã â¥24pt
â å¯å€§ãªç©ºçœïŒããŒãžã³ 5ã7 cmãããã«éé â¥3 cmïŒ
â åååã»åæ¥ããŽãªãïŒå
šäœã§äžè¬å INN â lecanemab ãdonanemab ïŒ
â ãã¹ãŠã®æ£è
ç¹å®æ
å ±ãåé€ïŒdefaced MRIãDOB ãªããã¢ã¯ã»ãã·ã§ã³çªå·ãªããé¡ãªãïŒ
â 該åœããå Žå Encore ã¹ããŒã¿ã¹ãæ£ãããã©ã°ãä»ã®æ¡ææé²ãšãµã©ãã¹ã©ã€ã¹éè€ãªã
â èè
é瀺㚠ISTAART æå±ã AAIC æ¹éã«åŸããªã³ã¯ãŸãã¯å°å·
â 25% ãºãŒã ã§ã¯ãªãå®å¯žã§å°å·æ ¡æ£ãã¬ãã¥ãŒ
â 3 åãŠã©ãŒã¯ã¹ã«ãŒã声ã«åºããŠå°ãªããšã 2 åãªããŒãµã«
æ¯å¹Žç¹°ãè¿ããããã¹ã¿ãŒæºåãšã©ãŒãããåºãé¿ããã«ã¯ã
ç ç©¶è
ãç¯ã 5 ã€ã®äžè¬çãªå³ã®ãã¹ ãåç
§ããŠãã ããã
FAQ
AAIC ãã¹ã¿ãŒããåã€ããã®ã«ããèŠçŽ ã¯äœã§ããïŒ
ãã¹ã¿ãŒããã¹ãã¯æäœã©ã®ãããå°ããã§ããŸããïŒ
AAIC ãã¹ã¿ãŒã§ Leqembi ã®ãããªãã©ã³ãè¬åã䜿ããŸããïŒ
AAIC ãã¹ã¿ãŒã§æ£è
åçãã¹ãã£ã³ããŒã¿ã瀺ããŸããïŒ
AAIC ã§ Beyond the Data ã¯éåžžã® Poster Presentation ãšã©ãéããŸããïŒ
å
責äºé
ïŒæ¬èšäºã¯äŒè°ãã¹ã¿ãŒããã³åºçç©åãã®ç§åŠçå³è¡šèšèšã®æè²çå
容ã§ãããå»åŠçå©èšã§ã¯ãããŸãã ãèšåºç倿ã«çšããã¹ãã§ã¯ãããŸãããæ¬èšäºã§èšåããçŸæ£ã¡ã«ããºã ãè¬å€é©å¿ãæ²»çãããã³ã«ã¯äžèšåŒçšæç®ããèŠçŽãããã®ã§ããèšåºå®åã«ãããŠã¯ãåèæç®ãå
¬åŒèšºçã¬ã€ãã©ã€ã³ãããã³æè³æ Œã®èšåºå»ã«çžè«ããŠãã ãããSciFig ã¯ç§åŠçã€ã©ã¹ãã¬ãŒã·ã§ã³ããŒã«ã§ããã蚺æãæ²»çããŸãã¯æ£è
管çã«é¢ããå©èšã¯è¡ããŸããã